111YI -5.65%51 EBITDA Margin % is -0.80% as of Mar. 2026. GuruFocus rates YI with a GF Score™ of 51/100 and a GF Value™ of $6.67 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 119 Medical Distribution companies, 111 ranks worse than 84.03% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. 111's EBITDA for the
three
months ended in Mar. 2026 was $-3 Mil. 111's Revenue for the
three
months ended in Mar. 2026 was $343 Mil. Therefore, 111's EBITDA margin for the quarter that ended in Mar. 2026 was -0.80%.
111 (NAS:YI) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
111 EBITDA Margin % Related Terms
111 EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for 111's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YI vs COSM, HKPD, VNOV: EBITDA Margin % Comparison
For the Medical Distribution subindustry, 111's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
111 EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, 111's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where 111's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
111 (YI) has a EBITDA Margin % of -0.80% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 111 and its competitors. According to the industry distribution chart, 111 ranks #100 out of 119 companies in the Medical Distribution industry, placing it in the top 84%.
Is 111's EBITDA Margin % too high?
111's current EBITDA Margin % is -0.80%. Based on the distribution chart, 111 ranks #100 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, 111 has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 111's EBITDA Margin % compare to COSM and HKPD?
According to the Medical Distribution industry distribution chart, 111 ranks #100 out of 119 companies for EBITDA Margin %. This places 111 in the lower half of its industry. The industry median EBITDA Margin % is 4.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 111 and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 111's current EBITDA Margin % is -0.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 111 stock overvalued right now?
Based on GuruFocus' analysis, 111 (YI) is currently considered Possible Value Trap. The stock's GF Value™ is $6.67, compared to a current price of $4.01 — trading 39.9% below its estimated fair value. The current EBITDA Margin % is -0.80%. 111's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For 111 (YI), the current EBITDA Margin % is -0.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 111 (YI) Overvalued in 2026?
Based on GuruFocus' analysis, 111 stock appears to be undervalued.
The current stock price of $4.01 is trading 39.9% below its estimated GF Value™ of $6.67.
GuruFocus considers 111 to be Possible Value Trap.
Key valuation signals for YI:
EBITDA Margin %: -0.80%
GF Value™: $6.67 vs. price of $4.01 (39.9% below fair value)
No single metric tells the full story. See the YI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
51GF Score
Get the complete analysis for YI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YI has been successfully added to your 
